trump glp-1 Novo, Lilly Shares Drop as Promises $150 Ozempic Trump administration makes deal to

No worrieswere here to help

A glucagon-like peptide-1 (GLP-1) drug appears to slow cognitive decline by protecting the brain, according to Phase 2b clinical trial results reported at AAIC.

Discover how this first-in-class oral GLP-1 receptor agonist works for type 2 diabetes, its FDA-approved uses, clinical benefits, and essential safety information for patients and providers.

People who took the daily pill orforglipron lost 12 percent of body weight on average after 72 weeks, according to clinical trial results from Lilly.

Mumbai: For thousands across the country, this year has brought a sudden relief from a lifetime of struggles with obesity, driven by the arrival of on.

Discover if Zepbound is the right treatment for you.